| All patients | PSA relapse | PSA persistence |
---|---|---|---|
ADT | |||
 ADT with stop before last follow up / duration (months) | 43 / 5 (2–25) | 22 / 4.5 (2–23) | 21 / 5.5 (2–25) |
 Ongoing ADT at last follow up | 30 | 3 | 27 |
 No ADT | 56 | 37 | 19 |
Median PSA before RT | 0.62 (< 0.03–40.13) | 0.44 (0.15–10.6) | 0.90 (< 0.03–40.13) |
RT | |||
 Former Prostate | 66 Gy (63–66) | ||
 Lymphatic pathways | 50.4 Gy (45–52.3) | ||
 Local recurrence | 70 Gy (66–70.6) | ||
 PET pos. LN | 61.6 Gy (53.2–66) | ||
RT technique | |||
 VMAT/IMRT & IGRT | All pts. | ||
Median Follow-up (months) | 20 (3–42) | ||
First PSA after RT | n = 121a | n = 58b | n = 63b |
 Median PSA | 0.07 (< 0.03–13.71) | 0.07 (< 0.03–0.56) | 0.07 (< 0.03–13.71) |
 PSA ≤ 0.1 ng/ml | 89 (74%) | 47 (81%) | 42 (67%) |
 PSA ≤ 0.2 ng/ml | 98 (81%) | 50 (86%) | 48 (76%) |
PSA at last median follow-up | n = 121a | n = 58b | n = 63b |
 Median PSA | 0.07 (< 0.03–35) | 0.07 (< 0.03–1) | 0.07 (0.01–35) |
 PSA ≤ 0.1 ng/ml | 82% | 87% | 77% |
 PSA ≤ 0.2 ng/ml | 84% | 91% | 78% |
PSA at last median follow-up with ADT | n = 30 | n = 2 | n = 28 |
 Median PSA | 0.06 (< 0.03–13.71) | < 0.03 | 0.07 (< 0.03–13.71) |
 PSA ≤ 0.1 ng/ml | 79% | 100% | 79% |
 PSA ≤ 0.2 ng/ml | 83% | 100% | 82% |
PSA at last median follow-up without ADT | n = 91 | n = 56 | n = 35 |
 Median PSA | 0.07 (< 0.03–35) | 0.07 (< 0.03–1) | 0.08 (< 0.03–35) |
 PSA ≤ 0.1 ng/ml | 83% | 87% | 78% |
 PSA ≤ 0.2 ng/ml | 85% | 91% | 78% |
PSA at last median follow-up in PET pos. pts | n = 72 | n = 29 | n = 43b |
 Median PSA | 0.06 (< 0.03–35) | 0.03 (< 0.03–0.46) | 0.07 (< 0.03–35) |
 PSA ≤ 0.1 ng/ml | 84% | 94% | 77% |
 PSA ≤ 0.2 ng/ml | 86% | 94% | 79% |
PSA at last median follow-up in PET pos. pts without ADT | n = 45 | n = 27 | n = 18 |
 Median PSA | 0.05 (< 0.03–35) | 0.04 (< 0.03–0.46) | 0.13 (< 0.03–35) |
 PSA ≤ 0.1 ng/ml | 89% | 94% | 82% |
 PSA ≤ 0.2 ng/ml | 89% | 94% | 82% |
PSA at last follow-up in PET neg. pts | n = 49 | n = 29 | n = 20 |
 Median PSA | 0.07 (< 0.03–3.23) | 0.07 (< 0.03–1) | 0.08 (< 0.03–3.23) |
 PSA ≤ 0.1 ng/ml | 78% | 79% | 77% |
 PSA ≤ 0.2 ng/ml | 83% | 87% | 77% |
Clinical Progress | |||
 Distant Metastases |  |  | 14 |